NMN / NMNH (NAD+ Precursors)

Nicotinamide adenine dinucleotide (NAD+) is arguably the most important coenzyme in human metabolism. It participates in over 500 enzymatic reactions, serves as the substrate for sirtuins (the longevity-associated deacetylases), fuels PARP DNA repair enzymes, and drives the mitochondrial electron transport chain. The problem: NAD+ levels decline approximately 50% between age 40 and 60 in most tissues, and this depletion is now mechanistically linked to nearly every hallmark of aging. Nicotinamide mononucleotide (NMN) and its reduced form NMNH are the most bioavailable precursors for restoring intracellular NAD+. Unlike niacin, which causes flushing at therapeutic doses, NMN and NMNH are well-tolerated. A landmark RCT published in Aging (PMC9400576) demonstrated that NMN 1250mg/day was safe and well-tolerated in 31 healthy adults, raising blood NAD+ significantly. Earlier work on nicotinamide riboside (NR), a closely related precursor, showed 1000mg/day raised NAD+ by 142% in a controlled trial (PMC6611812). The newer entrant, NMNH, has generated significant excitement in preclinical data: preliminary research suggests NMNH raises intracellular NAD+ approximately five times more potently than standard NMN, potentially due to differences in cellular transport efficiency. Human trial data remains limited but is actively being generated. A critical mechanistic insight published in Nature Metabolism (2020) reframed why NAD+ declines with age: senescent cells recruited CD38-expressing macrophages that act as NAD+ consumers, creating a pro-aging feedback loop where senescence drives NAD+ depletion, which in turn accelerates further senescence. This finding elevated NMN/NMNH from a simple energy supplement to a potential countermeasure against the senescent cell burden itself. Optimal dosing protocols favor sublingual NMN (500–1000mg/day) over oral capsules due to first-pass degradation. Combination with resveratrol, TMG (trimethylglycine for methyl donor support), and fasting protocols is common in the biohacking community, though synergy data remains largely anecdotal. NAD+ supplementation addresses genomic instability, mitochondrial dysfunction, epigenetic alterations, and cellular senescence simultaneously — one of the broadest mechanistic profiles in longevity science.